Miracle medicine for prevention of migraine attack: Metformin.

Abstract

Objectives: In search of effective and economical option for prophylaxis of Migraine evaluating the prophylactic role of Metformin in migraine. Study Design: Single blind placebo controlled trial. Setting: Department of Pharmacology BMSI, JPMC, in collaboration with Sindh services Hospital Karachi. Period: April 2017 – August 2018. Material & Methods: A total 105 patients with diagnosed migraine were included in this trial. Total patients were equally divided into 3 groups designated Groups A, B, and C that were representative of Placebo, Metformin and Propranolol groups respectively. Total study duration was 6 months, which were equally divided into 2 phases. First 3 month phase was baseline period and later one was treatment period. The primary parameters for evaluating the prophylactic role of Metformin in Migraine were Migraine integral Burden scale (MIBS), HIT-6, MIDAS, MPQ-5, frequency of migraine attack per month. Results: At baseline there were statistically non-significant differences found for MIBS (F (2,102) = 0.346, p = 0.708), MIDS (F (2,102) =0.248, p=0.781), MPQ (F (2,102) =0.188, p=0.828) and severity of headache (F (2,102) =0.247, p=0.782) among all treated groups. But at final follow up there was highly significant difference were found among all treated groups for all parameters. Pairwise comparison showed significant differences between group A and B and group A and C was recorded for all parameters. Nevertheless there was no difference seen in group B and C (mean difference (MD) = -0.171 ± 0.149, p= 0.485) ,(MD= -0.143±0.132,p=0.526), (MD = - 2.057±0.301, p<0.001), (MD = -0.314±0.360, p=0.658), (MD = -0.514 ± 0.288, p = 0.179), (MD= 0.00±0.149, p=1.00) for MIBS, migraine frequency, HIT-6, MIDS, MRQ, headache severity respectively. Conclusion: This study demonstrated that Metformin is valuable, safer and economical option for preventive measure of Migraine.